Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
Recruiting · NCT07059923 · Observational (researchers observe without assigning treatment) · Lead sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
View the official record on ClinicalTrials.gov →What this trial is about
CT imaging data from lung cancer (NSCLC and SCLC) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients were treated for lung cancer in Wuhan Union Hospital from July 2025 to July 2026;
- Aged \> 18 years old;
- At least one CT scan before treatment;
- Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.
Exclusion criteria
- Poor image quality;
- Incomplete clinical data or loss of follow-up;
- Presence of another primary malignancy other than lung cancer;
- Unclear pathological diagnosis.
Where it is running
1 location listed.
- Union Hospital，Tongji Medical College，Huazhong University of Science and Technology - Wuhan, Hubei, China